The loss of CD55 and CD59 renders PNH erythrocytes vulnerable to complement-mediated intravascular hemolysis [11,12], which results in clinical manifestations of PNH, including hemolytic anemia, thrombosis, cytopenias, and renal insufficiency [13]. This evidence concerns the gene CD59 and paroxysmal nocturnal hemoglobinuria.